Evidence map›Paper›PMID 22797059›Full record

ArticleOncogene2013

Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs.

S Das, K Bryan, P G Buckley, O Piskareva, I M Bray, N Foley, J Ryan, J Lynch, L Creevey, J Fay and 11 more

Open access · bronzeAbstract read
In one paragraph

Article in Oncogene, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Epigenetic crosstalk in neuroblastoma development and progression.Frontiers in cell and developmental biology · 2026
    Review
  3. Article
  4. Review
  5. Divergent Functions of Rap1A and Rap1B in Endothelial Biology and Disease.International journal of molecular sciences · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. miR-340: A multifunctional role in human malignant diseases.International journal of biological sciences · 2021
    Review
  15. [Role of miRNA-340 in modulating gastric cancer cell proliferation and bioinformatic analysis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2019
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 4 countries.

S DasDepartment of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland.
K Bryan
P G Buckley
O Piskareva
I M Bray
N Foley
J Ryan
J Lynch
L Creevey
J Fay
S Prenter
J Koster
P van Sluis
R Versteeg
A Eggert
J H Schulte
A Schramm
P Mestdagh
J Vandesompele
F Speleman
R L Stallings
Royal College of Surgeons in Ireland · IENational Children’s Research Centre · IEEssen University Hospital · DEGhent University Hospital · BEAcademic Medical Center · NLUniversity of Amsterdam · NL

Funding

MiRNA Expression in NeuroblastomaR01CA127496 · NCI · ROYAL COLLEGE OF SURGEONS IN IRELAND · PI STALLINGS, RAYMOND LOUIS · 2008 to 2012
$976k
NCI NIH HHS 5R01CA127496NCI NIH HHS R01 CA127496
6 · The paper itself

Abstract

MicroRNAs (miRNAs) contribute to the pathogenesis of many forms of cancer, including the pediatric cancer neuroblastoma, but the underlying mechanisms leading to altered miRNA expression are often unknown. Here, a novel integrated approach for analyzing DNA methylation coupled with miRNA and mRNA expression data sets identified 67 epigenetically regulated miRNA in neuroblastoma. A large proportion (42%) of these miRNAs was associated with poor patient survival when underexpressed in tumors. Moreover, we demonstrate that this panel of epigenetically silenced miRNAs targets a large set of genes that are overexpressed in tumors from patients with poor survival in a highly redundant manner. The genes targeted by the epigenetically regulated miRNAs are enriched for a number of biological processes, including regulation of cell differentiation. Functional studies involving ectopic overexpression of several of the epigenetically silenced miRNAs had a negative impact on neuroblastoma cell viability, providing further support to the concept that inactivation of these miRNAs is important for neuroblastoma disease pathogenesis. One locus, miR-340, induced either differentiation or apoptosis in a cell context dependent manner, indicating a tumor suppressive function for this miRNA. Intriguingly, it was determined that miR-340 is upregulated by demethylation of an upstream genomic region that occurs during the process of neuroblastoma cell differentiation induced by all-trans retinoic acid (ATRA). Further biological studies of miR-340 revealed that it directly represses the SOX2 transcription factor by targeting of its 3'-untranslated region, explaining the mechanism by which SOX2 is downregulated by ATRA. Although SOX2 contributes to the maintenance of stem cells in an undifferentiated state, we demonstrate that miR-340-mediated downregulation of SOX2 is not required for ATRA induced differentiation to occur. In summary, our results exemplify the dynamic nature of the miRNA epigenome and identify a remarkable network of miRNA/mRNA interactions that significantly contribute to neuroblastoma disease pathogenesis.

Indexed as

3' Untranslated RegionsCell Line, TumorComputational BiologyDNA MethylationEpigenesis, GeneticGene Regulatory NetworksGenomicsHumansMicroRNAsNeuroblastomaSOXB1 Transcription FactorsSurvival AnalysisTretinoin3' Untranslated RegionsMicroRNAsMIRN340 microRNA, humanSOX2 protein, humanSOXB1 Transcription FactorsTretinoin

Identifiers

PMID22797059
PMCPMC3477279
OpenAlexW2006417904

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.